LISI SA

LISI SA

59.80
EUR
-1.70
(-2.76%)
3.01BMarket Cap
Feb 18Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
21.92
24.85
27.62
29.7
30.98
30.92
32.49
23.24
21.98
26.93
36.06
35.31
38.24
- -
Basic EPS, GAAP
1.42
1.55
1.55
2.02
2.04
1.73
1.31
-0.71
0.83
1.08
0.83
1.23
3.06
- -
Free Cash Flow per Basic Share
0.57
0.92
0.82
1.25
3.62
3.65
1.98
2.14
1.01
0.44
0.84
1.76
2.11
- -
Dividend per Share
0.28
0.34
0.37
0.39
0.45
0.48
0.44
- -
0.14
0.29
0.18
0.31
0.39
- -
Book Value per Share
11.93
13.48
15.01
16.26
16.78
17.66
19
18.66
19.83
21.07
20.51
21.94
23.73
24.95
Tangible Book Value per Share
8.33
8.29
9.79
10.13
10.15
10.6
11.79
11.82
11.72
12.65
10.93
12.08
16.24
17.37
Basic Weighted Avg Shares
52
53
53
53
53
53
53
53
53
53
45
46
46
46
Sales/Revenue/Turnover
1,149
1,307
1,458
1,571
1,643
1,645
1,730
1,230
1,164
1,425
1,630
1,609
1,748
- -
Operating Margin (%)
11.19
10.09
10.05
10.02
10.43
8.24
8.97
3.37
5.72
6.25
5.56
6.14
9.21
- -
Depreciation Expense
61
67
71
81
90
99
119
117
96
97
100
110
98
- -
Net Income, GAAP
75
81
82
107
108
92
70
-37
44
57
38
56
140
- -
Effective Tax Rate (%)
33.04
34.34
34.28
33.85
26.5
25.9
27.44
- -
33.13
26.59
39.64
27.12
27.91
- -
Profit Margin (%)
6.5
6.24
5.61
6.81
6.57
5.6
4.03
-3.03
3.78
4
2.3
3.48
7.99
- -
Working Capital
258
332
353
311
343
320
398
322
301
313
303
383
496
456
LT Debt
119
246
230
254
319
338
412
317
321
328
494
547
395
351
Total Equity
626
710
793
865
898
944
1,021
990
1,053
1,118
939
1,006
1,091
1,143
Return on Invested Capital (%)
9.99
9.46
8.9
8.49
9.41
6.55
5.29
- -
2.5
4.23
3.5
3.38
6.11
- -
Return on Capital (%)
9.97
9.49
8.31
9.65
8.64
6.47
4.7
- -
3.2
4.01
3.24
4.83
9.65
- -
Return on Common Equity (%)
12.44
12.21
10.89
12.95
12.34
10.08
7.16
-3.73
4.32
5.26
3.66
5.8
13.41
- -

Capital Structure

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
255
109
161
LT Borrowings
428
297
237
LT Finance Leases
93
98
113
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
46
46
46
Market Capitalization
1,726
2,386
3,008

Working Capital

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
1,048
999
1,074
Cash, Cash Equivalents & STI
255
270
247
Accounts Receivable, Net
210
155
213
Inventories
498
461
518
Total Current Liabilities
672
503
617
Payables & Accruals
- -
- -
- -
ST Debt
255
109
161
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.52%
2.42%
8.43%
Free Cash Flow
29.09%
17.1%
20.47%
Net Income, GAAP
-18.48%
-4.82%
149.48%
Sales/Revenue/Turnover
2.75%
7.76%
8.65%
Total Cash Common Dividend
- -
- -
26.08%

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1,609
2025
- -
- -
1,748
2026
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1.23
2025
- -
- -
3.06
2026
- -
- -
- -

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.31
2025
- -
- -
0.39
2026
- -
- -
- -

Company Description

CEO
Emmanuel Viellard
Full Time Employees
9,634
Sector
Electronic technology
Industry
Aerospace & defense
Address
6 rue JuvEnal Viellard Belfort BFC France 90008
IPO Date
Jan 1, 1989
Business
Lisi S.A. designs, manufactures and markets high-technology mechanical fastener systems and assembly components primarily for the aerospace, automotive and medical sectors worldwide; its core offerings encompass fasteners including screws, bolts, nuts and washers; clipped fastening solutions such as panel fasteners, clipped nuts and anti-creep rings; structural components like aircraft engine blades, landing gear and helicopter rotors; automotive braking systems, seating, safety and fuel components; and medical implants, reconstruction instruments and mini-invasive surgery tools including orthopedic, spine, cardiovascular and neuro-cerebral products under brands such as OPTIBLIND, TYX and RIB fittings. The company operates through three main divisions, LISI Aerospace, LISI Automotive and LISI Medical, with 42 production sites across Europe, North America and Asia; it serves major original equipment manufacturers in aeronautics, defense, passenger vehicles and medtech. Founded in 1777 and headquartered in Belfort, France, Lisi S.A. employs over 10,000 people and generates annual revenue of approximately €1.85 billion as of 2024. Recent major changes include the October 2025 sale of its LISI Medical division to SK Capital Partners, which was rebranded Precera Medical with Lisi retaining a nearly 10% minority stake to support future growth; the September 2025 acquisition by LISI Automotive Hungary of Polysemble Hungary assets to bolster automotive capabilities; divestiture of LISI Automotive Nomel SAS to ZB Invest in February 2025 as part of strategic refocusing; and ongoing investments in automation, capacity expansion and R&D representing about 6% of revenue for advanced fastening innovations. Listed on Euronext Paris under ticker FII.PA since 1989, the company continues to adapt to industry shifts toward lighter, electrified vehicles and decarbonized aerospace through targeted partnerships and operational enhancements.